Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3758976
Max Phase: Preclinical
Molecular Formula: C24H38ClN5O4
Molecular Weight: 496.05
Molecule Type: Small molecule
Associated Items:
ID: ALA3758976
Max Phase: Preclinical
Molecular Formula: C24H38ClN5O4
Molecular Weight: 496.05
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(CC2CCN(C(=O)NC(C)C)CC2)C[C@H]1OC
Standard InChI: InChI=1S/C24H38ClN5O4/c1-15(2)27-24(32)30-9-5-16(6-10-30)13-29-8-7-20(22(14-29)34-4)28-23(31)17-11-18(25)19(26)12-21(17)33-3/h11-12,15-16,20,22H,5-10,13-14,26H2,1-4H3,(H,27,32)(H,28,31)/t20-,22+/m0/s1
Standard InChI Key: UMVIPSLAOJCGEP-RBBKRZOGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 496.05 | Molecular Weight (Monoisotopic): 495.2612 | AlogP: 2.58 | #Rotatable Bonds: 7 |
Polar Surface Area: 109.16 | Molecular Species: BASE | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.03 | CX LogP: 1.02 | CX LogD: -0.61 |
Aromatic Rings: 1 | Heavy Atoms: 34 | QED Weighted: 0.50 | Np Likeness Score: -1.16 |
1. Park JS, Im W, Choi S, Park SJ, Jung JM, Baek KS, Son HP, Sharma S, Kim IS, Jung YH.. (2016) Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent., 109 [PMID:26761776] [10.1016/j.ejmech.2015.12.006] |
Source(1):